Beyond Celiac pushes pediatric trial talks with FDA

Beyond Celiac Coalition met with the FDA and families to discuss the barriers to pediatric celiac disease trials, a step advocates say is needed before new therapies can be tested in children. The conversation is meant to shape trial designs that patients and parents could actually accept.

Why it matters: - Pediatric clinical trials have not yet been conducted in celiac disease. - Without pediatric studies, therapies developed for celiac disease may not be usable for children. - Adult celiac trials can struggle to enroll participants because many study procedures are seen as invasive or debilitating. - The FDA discussion focused on making future pediatric trials more patient-centric and more realistic for families.

What happened: - The Beyond Celiac Coalition met with the FDA, pediatric celiac disease patients and their parents. - The meeting centered on barriers to pediatric clinical trials for celiac disease. - The group discussed what pediatric trials could look like and what families might consider acceptable. - This was the second time the Beyond Celiac Coalition convened stakeholders and FDA representatives to discuss celiac disease severity and therapy goals.

The details: - The coalition is a collaboration of multidisciplinary stakeholders working to develop potential treatments for celiac disease. - Beyond Celiac leads the coalition. - Coalition members include patient organizations, academic and clinical celiac disease specialists, and professional societies. - Participating societies include the American Gastroenterological Association, the North American Society for Pediatric Gastroenterology, Hepatology and Nutrition, The American College of Gastroenterology, and the International Society for the Study of Celiac Disease. - Academic and clinician members include Imad Absah, MD; Robert Anderson, MBChB BMedSc PhD; Amanda Cartee, MD; Shayna Coburn, PhD; Lisa Fahey, MD; Edwin Liu, MD; Stephanie Moleski, MD; Joseph A. Murray, MD; Marie Robert, MD; Jocelyn Silvester, MD, PhD; Marisa Stahl, MD; and Adam C. Stein, MD. - Industry members include First Tracks Bio, Chugai Pharmaceutical Co., Sanofi, Takeda, Alimentiv Inc, Eli Lilly, and Teva Pharmaceuticals, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. - Kate Avery, MPH, senior director of science with Beyond Celiac, said patient perspectives are essential when designing celiac disease trials. - Debra Silberg, MD, PhD, chief scientific officer at Beyond Celiac, said pediatric trial planning needs to start now so children are not left behind as treatments advance. - Beyond Celiac was founded in 2003. - The organization describes itself as the leading catalyst for a celiac disease cure in the United States.

Between the lines: - The meeting signals that regulators, researchers, companies and patients are trying to align early on trial design rather than after a therapy is already ready for testing. - Pediatric trial barriers are a known gap in celiac research, so the discussion suggests the field is moving from general treatment ambition to practical planning. - Patient input matters especially here because trial burden can determine whether studies recruit enough participants.

What's next: - The coalition is expected to keep identifying barriers to celiac disease treatment development. - Future pediatric trial discussions will likely focus on acceptable procedures, family burden and how to design studies that can recruit children. - The coalition’s broader work will continue across industry, academic and clinical stakeholders as therapies move forward.

The bottom line: - The FDA meeting marks an early effort to clear the path for pediatric celiac disease trials before treatment candidates reach children.